Acumen Pharmaceuticals, Inc. Common Stock

ABOS XNAS • BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)

Historical Short Interest Share

Chase Ink Business Preferred®

Earn Up to 150K Bonus Points

Transfer points to 14+ airline & hotel partners. Up to 40% upgrade value on first class travel. $95/yr.

Apply Now

Market Cap

170M

Short interest (May 15)

2.4%

Net Short (Jun 03 ): 0.0%

Borrow Fee

0.67%

↓ 68.9%

Available Shares

↓ 21.6%

Price Chart

Company Overview

Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers. The product pipelines include: ALTITUDE-AD; and INTERCEPT-AD.

Company Info

Exchange: NASDAQ

Industry: BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)

CIK: 0001576885

Asset Type: CS

Market Data

Market Cap: $171,179,364

Employees: 61

Status: Active

Short Interest

Current Borrow Fee 0.67%

Range: 0.27% - 0.67%

Available Shares 1M

Range: 750K - 1M

Recent Changes

Fee Change: ↑ 76.1%

Available Change: ↓ 5.0%

Quick Actions

View Dilution Chart

Add to Watchlist Set Price Alert View Options Chain

Investment Risk

This is not financial advice. All investments carry risk. Do your own research before making investment decisions.

Weekly Research

Get Weekly Super Stonk Alerts

Never miss a squeeze opportunity. Get our weekly analysis of high short interest stocks, AI-discovered gems, and dilution warnings delivered to your inbox.

No spam • Unsubscribe anytime